ReviewFrontiers in pharmacology2021
Microbiota and Colorectal Cancer: From Gut to Bedside.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Targeting the human gut microbiome: a comparative review of probiotics, prebiotics, synbiotics, and postbiotics.Journal of advanced research · 2026Review
- Review
- Exploring the Role of Probiotics in the Prevention and Treatment of Gastrointestinal Cancer.Probiotics and antimicrobial proteins · 2026Review
- The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.Frontiers in immunology · 2026Review
- The role of probiotics in modulating complications and intestinal barrier integrity after colorectal cancer surgery: a systematic review and meta-analysis of clinical trials.Gastroenterology and hepatology from bed to bench · 2026Review
- [Causal relationship between gut microbiota and T cell subsets in the development of colorectal cancer: a Mendelian randomization analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Comprehensive analysis of transcriptome and microbiome in colorectal cancer with synchronous polyp patients.Frontiers in cellular and infection microbiology · 2025Article
- Gut microbiota - bidirectional modulator: role in inflammatory bowel disease and colorectal cancer.Frontiers in immunology · 2025Review
- Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives.Exploration of targeted anti-tumor therapy · 2025Review
- Assessment of the relationship between gut microbiota, inflammatory markers, and colorectal cancer.Frontiers in cellular and infection microbiology · 2025Article
- Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.Cancer innovation · 2024Review
- Review
- Mineral crude drug mirabilite (Mangxiao) inhibits the occurrence of colorectal cancer by regulating theMedComm · 2024Article
- Unlocking the secrets: exploring the influence of the aryl hydrocarbon receptor and microbiome on cancer development.Cellular & molecular biology letters · 2024Review
- Involvement of the Gut Microbiome in the Local and Systemic Immune Response to Pancreatic Ductal Adenocarcinoma.Cancers · 2024Review
- Identification of key programmed cell death genes for predicting prognosis and treatment sensitivity in colorectal cancer.Frontiers in oncology · 2024Article
- Colorectal cancer-specific microbiome in peripheral circulation and cancer tissues.Frontiers in microbiology · 2024Article
- CT-Based Radiomics to PredictBiomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a complex condition with heterogeneous aetiology, caused by a combination of various environmental, genetic, and epigenetic factors. The presence of a homeostatic gut microbiota is critical to maintaining host homeostasis and determines the delicate boundary between health and disease. The gut microbiota has been identified as a key environmental player in the pathogenesis of CRC. Perturbations of the gut microbiota structure (loss of equilibrium and homeostasis) are associated with several intestinal diseases including cancer. Such dysbiosis encompasses the loss of beneficial microorganisms, outgrowth of pathogens and pathobionts and a general loss of local microbiota diversity and richness. Notably, several mechanisms have recently been identified how bacteria induce cellular transformation and promote tumour progression. In particular, the formation of biofilms, the production of toxic metabolites or the secretion of genotoxins that lead to DNA damage in intestinal epithelial cells are newly discovered processes by which the microbiota can initiate tumour formation. The gut microbiota has also been implicated in the metabolism of therapeutic drugs (conventional chemotherapy) as well as in the modulation of radiotherapy responses and targeted immunotherapy. These new findings suggest that the efficacy of a given therapy depends on the composition of the host's gut microbiota and may therefore vary from patient to patient. In this review we discuss the role of host-microbiota interactions in cancer with a focus on CRC pathogenesis. Additionally, we show how gut bacteria can be exploited in current therapies and how mechanisms directed by microbiota, such as immune cell boost, probiotics and oncolytic bacteria, can be applied in the development of novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.